Nurix Therapeutics (NASDAQ:NRIX) Stock Keeps Buy Rating at Needham & Company LLC

Nurix Therapeutics (NASDAQ:NRIX)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $34.00 price target on the stock. Needham & Company LLC’s price target indicates a potential upside of 52.36% from the company’s current price.

Several other equities analysts have also recently weighed in on the company. Robert W. Baird raised their price target on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday. HC Wainwright raised their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Oppenheimer assumed coverage on Nurix Therapeutics in a report on Monday, June 29th. They set an “outperform” rating and a $28.00 price target for the company. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Finally, Mizuho lifted their target price on Nurix Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.64.

Nurix Therapeutics Stock Up 0.7%

NASDAQ NRIX traded up $0.16 during trading on Tuesday, hitting $22.32. 496,444 shares of the stock traded hands, compared to its average volume of 1,468,342. The company has a market capitalization of $2.32 billion, a P/E ratio of -6.47 and a beta of 1.82. The firm has a 50-day simple moving average of $25.22 and a 200-day simple moving average of $20.96. Nurix Therapeutics has a 12-month low of $9.14 and a 12-month high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $5.33. The business had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%. As a group, research analysts predict that Nurix Therapeutics will post -2.69 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Hans van Houte sold 4,761 shares of Nurix Therapeutics stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total value of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. The trade was a 10.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 4,356 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $25.00, for a total value of $108,900.00. Following the sale, the insider directly owned 117,227 shares of the company’s stock, valued at $2,930,675. This represents a 3.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 21,372 shares of company stock valued at $518,463. Company insiders own 6.70% of the company’s stock.

Institutional Investors Weigh In On Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NRIX. GAMMA Investing LLC lifted its stake in shares of Nurix Therapeutics by 95.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after acquiring an additional 620 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Nurix Therapeutics by 755.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,014 shares of the company’s stock worth $95,000 after acquiring an additional 3,545 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $33,000. Nykredit A S bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $32,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $341,000.

Nurix Therapeutics News Summary

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix reported third-quarter earnings of $4.73 per share, dramatically exceeding analyst expectations for a loss of approximately $0.56–$0.60 per share and improving from a $1.03 loss a year earlier. Revenue of $673.06 million also surpassed the approximately $24 million consensus estimate. Nurix Therapeutics Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The earnings release included a significant development for Nurix’s pipeline: the company dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial. The study is evaluating bexobrutideg against pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, advancing the program toward potential commercialization. Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Robert W. Baird raised its price target from $33 to $36 and maintained an “outperform” rating. Needham reaffirmed its “buy” rating with a $34 target, while Truist maintained a “buy” rating despite trimming its target from $34 to $33. Collectively, the targets imply substantial potential upside from the current reference price.
• Neutral Sentiment: The reported profit and revenue surge should be interpreted cautiously because Nurix still posted a deeply negative net margin and return on equity. Investors may focus on whether the quarter’s unusually large results are repeatable and how clinical-trial progress affects future cash needs.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.